



## Caladrius Biosciences to Participate at the Upcoming May Conferences

May 7, 2019

**BASKING RIDGE, N.J.** – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announced today that management will participate in the following conferences in May:

### 16<sup>th</sup> International Symposium on Cardiovascular Regeneration and Repair

Title: *The Microcirculation: Center of the Cardiovascular Repair Universe*

Date & Time: Thursday, May 9, 2019 at 4:30 p.m. (GMT+2)

Presenter: Douglas Losordo, M.D., FACC, FAHA, Executive Vice President, Global Head of Research and Development, Chief Medical Officer

Venue: Hospital General Universitario Gregorio Marañón, Aula Magna del Pabellón Docente in Madrid, Spain

### 2019 World Advanced Therapies & Regenerative Medicine Congress

#### Oral Presentation:

Title: *Single Administration of CD34 cell Reverses Cardiovascular disease: Evidence from >700 patients in randomized clinical trials*

Date & Time: Thursday, May 16, 2019 at 4:05 p.m. (GMT+1)

Presenter: Douglas Losordo, M.D., FACC, FAHA, Executive Vice President, Global Head of Research and Development, Chief Medical Officer

Dr. Losordo will also participate in a panel discussion, entitled, “*Clinical Development of Cell Therapies (CAR-T, DCs, Tregs etc.)*,” on Thursday, May 16, 2019 at 5:45 p.m. (GMT+1).

#### Corporate Presentation:

Topic: Company Overview

Date & Time: Thursday, May 16, 2019 at 4:15 p.m. (GMT+1)

Presenter: David Mazzo, Ph.D., President and Chief Executive Officer

The 2019 World Advanced Therapies & Regenerative Medicine Congress will be held at the Business Design Centre in London, England.

### About Caladrius Biosciences

Caladrius is a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. The Company’s goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; CLBS14-CMD, in Phase 2 testing for the treatment of coronary microvascular dysfunction; and CLBS14-NORDA (formerly CLBS14-RfA) in late-stage development for no option refractory disabling angina for which it has received RMAT designation. For more information on the company, please visit [www.caladrius.com](http://www.caladrius.com).

### Contact:

Investors:

Caladrius Biosciences, Inc.

John Menditto

Vice President, Investor Relations and Corporate Communications

Phone: +1-908-842-0084

Email: [jmenditto@caladrius.com](mailto:jmenditto@caladrius.com)



Source: Caladrius Biosciences, Inc.